Connect Biopharma Holdings Limited

NASDAQ:CNTB

Biotechnology

Healthcare
$0.80 -4.09%

-$0.09 today

Market cap
$50.52M
Beta
-0.21
P/E (TTM)
-4.0
EPS (TTM)
-$0.50
52W Low $0.91High $3.82

Volume 2.50M

Average 0.30M

CNTB Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Connect Biopharma Holdings LimitedNASDAQ: CNTB

Investing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Investing cash flow turns positive

Q4 FY2025 investing cash flow was $10.98M, compared with -$15.72M a year earlier.

Context

  • Investing cash flow amounted to 15340.6% of revenue in FY2025, up 15327.4 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$10.98M— QoQ
Last fiscal yearDec 2025
$9.82M+384.5% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+169.9%——
1 year+384.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
9.82M USD
Year-over-year change
+384.5%

Investing Cash Flow vs competitors

How CNTB compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +384.5% is the highest of 8, against a peer median of -99.1%.
  • Investing cash flow amounts to 15340.6% of revenue for CNTB, versus a peer median of 362.1%.
CNTB Competitors
Investing Cash Flow for CNTB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KLRSKalaris Therapeutics IncLTM Mar 2026$70.07M USD———
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$68.76M USD+157.2%——
OVIDOvid Therapeutics Inc.LTM Mar 2026$49.01M USD-224.0%-17.2%688.1%
STROSutro Biopharma, Inc.LTM Mar 2026$16.01M USD-88.4%—16.1%
IMAImageneBio IncLTM Mar 2026$14.19M USD-165.2%-61.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$9.82M USD+384.5%—15340.6%
IFRXInflaRx N.V.LTM Mar 2026€8.18M EUR-119.0%-45.7%27899.4%
CNTXContext Therapeutics Inc.LTM Mar 2026$2.04M USD-86.2%+55.9%—
STTKShattuck Labs, Inc.LTM Mar 2026$361K USD-99.1%—36.1%
Peer median (excluding CNTB) —-99.1%-31.4%362.1%

Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(204.94M)(116.12M)(59.38M)(15.63M)(55.48M)
Depreciation & Amortization640.98K1.01M988K660K704K
Deferred Income Tax106.37M3.37M000
Stock-Based Compensation1.41M1.01M3.26M6.73M3.73M
Change in Working Capital3.27M7.16M9.49M(15.49M)580K
Accounts Receivables(2.53K)3.37K1.04M(789K)776K
Inventory2.53K(3.37K)000
Accounts Payables8.89M375.66K(4.28M)(1.87M)1.62M
Other Working Capital(5.62M)6.78M12.72M(12.83M)(1.82M)
Other Non-Cash Items6.91K(1.35M)(2.28M)118K(736K)
Operating Cash Flow(85.57M)(99.27M)(47.93M)(23.61M)(51.21M)
Capital Expenditures(7.46M)(4.28M)(294K)(750K)(434K)
Acquisitions (Net)47.74K79.16K2.94M00
Purchases of Investments(17.98M)(113.7M)(32.6M)(15.45M)(30.47M)
Sales of Investments20.1M34.54M105.19M12.63M39.95M
Other Investing Activities(47.74K)(79.16K)(84K)123K775K
Investing Cash Flow(5.34M)(83.44M)75.16M(3.45M)9.82M
Debt Repayment(126K)(222K)(290K)00
Common Stock Issued219.99M18K44K227K1.09M
Common Stock Repurchased(566K)0000
Dividends Paid00000
Other Financing Activities(19.12M)119K000
Financing Cash Flow206.66M(91.29K)(246K)227K1.09M
Effect of Forex Changes(6.34M)13.87M18K(595K)408K
Net Change in Cash109.42M(168.93M)27M(27.43M)(39.89M)
Free Cash Flow(93.03M)(103.55M)(48.22M)(24.36M)(51.64M)

Connect Biopharma Holdings Limited

NASDAQ:CNTB

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.